Determination of the composition, encapsulation efficiency and loading capacity in protein drug delivery systems using circular dichroism spectroscopy

被引:53
作者
Peng, Zhili [1 ]
Li, Shanghao [1 ]
Han, Xu [1 ]
Al-Youbi, Abdulrahman O. [2 ]
Bashammakh, Abdulaziz S. [2 ]
El-Shahawi, Mohammad S. [2 ]
Leblanc, Roger M. [1 ]
机构
[1] Univ Miami, Dept Chem, 1301 Mem Dr, Coral Gables, FL 33146 USA
[2] King Abdulaziz Univ, Fac Sci, Dept Chem, POB 80203, Jeddah 21589, Saudi Arabia
关键词
Peptide and protein; Drug delivery; Encapsulation efficiency; Loading capacity; Circular dichroism spectroscopy; IMMUNE-SYSTEM; THERAPEUTICS; THERAPY; FUTURE; DERMATOMYOSITIS; NANOPARTICLES; POLYMYOSITIS; VESICLES; RELEASE;
D O I
10.1016/j.aca.2016.08.014
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Peptides and proteins have become very promising drug candidates in recent decades due to their unique properties. However, the application of these drugs has been limited by their high enzymatic susceptibility, low membrane permeability and poor bioavailability when administered orally. Considerable efforts have been made to design and develop drug delivery systems that could transport peptides and proteins to targeted area. Although it is of great importance to determine the composition after loading a drug to the carrier, the ability to do so is significantly limited by current analytical methods. In this letter, five important proteins, alpha(1)-antitrypsin, hemoglobin human, human serum albumin, human transferrin and r-globulin were chemically conjugated to two model drug carriers, namely carbon dots and polymer O-(2-carboxyethyl)polyethylene glycol. A simple yet convenient method based on circular dichroism spectroscopy was developed to determine the compositions of the various protein-carrier conjugates. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 35 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]  
Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/TDE.13.104, 10.4155/tde.13.104]
[3]  
CHERIN P, 1994, J RHEUMATOL, V21, P1092
[4]   Treatment of dermatomyositis and polymyositis [J].
Choy, EHS ;
Isenberg, DA .
RHEUMATOLOGY, 2002, 41 (01) :7-13
[5]  
Chung JE, 2014, NAT NANOTECHNOL, V9, P907, DOI [10.1038/NNANO.2014.208, 10.1038/nnano.2014.208]
[6]   The Future of Peptide-based Drugs [J].
Craik, David J. ;
Fairlie, David P. ;
Liras, Spiros ;
Price, David .
CHEMICAL BIOLOGY & DRUG DESIGN, 2013, 81 (01) :136-147
[7]   Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design [J].
El-Say, Khalid Mohamed .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :825-839
[8]   Nanoparticulate inorganic UV absorbers: a review [J].
Fajzulin, Igor ;
Zhu, Xiaomin ;
Moeller, Martin .
JOURNAL OF COATINGS TECHNOLOGY AND RESEARCH, 2015, 12 (04) :617-632
[9]   Human serum albumin: From bench to bedside [J].
Fanali, Gabriella ;
di Masi, Alessandra ;
Trezza, Viviana ;
Marino, Maria ;
Fasano, Mauro ;
Ascenzi, Paolo .
MOLECULAR ASPECTS OF MEDICINE, 2012, 33 (03) :209-290
[10]   Peptide therapeutics: current status and future directions [J].
Fosgerau, Keld ;
Hoffmann, Torsten .
DRUG DISCOVERY TODAY, 2015, 20 (01) :122-128